Hyperfine, Inc. (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.
The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients. Hyperfine’s portable MRI is configured for rapid, point-of-care imaging of the brain and central nervous system, with applications spanning stroke evaluation, traumatic brain injury assessment and routine neurological monitoring. The system’s cloud-based image management and AI-assisted processing tools help streamline workflow and accelerate diagnostic decision-making.
Founded in 2014 and headquartered in Guilford, Connecticut, Hyperfine secured U.S. Food and Drug Administration 510(k) clearance for its portable MRI in 2020 and obtained CE mark authorization for its European operations in 2021. The company completed its business combination and began trading publicly on Nasdaq in 2022. Hyperfine continues to expand its commercial footprint across the United States and selective international markets, partnering with hospitals, health systems and research institutions to integrate portable MRI into standard clinical practice.
AI Generated. May Contain Errors.
